Beta3-tubulin is induced by estradiol in human breast carcinoma cells through an estrogen-receptor dependent pathway.

Microtubules are involved in a variety of essential cell functions. Their role during mitosis has made them a target for anti-cancer drugs. However development of resistance has limited their use. It has been established that enhanced beta3-tubulin expression is correlated with reduced response to antimicrotubule agent-based chemotherapy or worse outcome in a variety of tumor settings. However little is known regarding the regulation of beta3-tubulin expression. We investigated the regulatory mechanisms of expression of beta3-tubulin in the MCF-7 cell line, a model of hormone-dependent breast cancer. Exposure of MCF-7 cells to estradiol was found to induce beta3-tubulin mRNA as well as beta3-tubulin protein expression. Conversely, we did not observe induction of beta3-tubulin mRNA by estradiol in MDA-MB-231 cells which are negative for the estrogen receptor (ER). In order to determine whether beta3-tubulin up-regulation is mediated through the ER pathway, MCF-7 cells were exposed to two ER modulators. Exposure to tamoxifen, a selective estrogen receptor modulator, completely abolished the beta3-tubulin mRNA induction due to estradiol in MCF-7 cells. This result was confirmed with fulvestrant, a pure antagonist of ER. These results demonstrate that the effect of estradiol on beta3-tubulin transcription is mediated through an ER dependent pathway.

[1]  Sanda Raulic,et al.  Stanniocalcin 2 expression is regulated by hormone signalling and negatively affects breast cancer cell viability in vitro. , 2008, The Journal of endocrinology.

[2]  B. Katzenellenbogen,et al.  Estrogen receptor regulation of carbonic anhydrase XII through a distal enhancer in breast cancer. , 2008, Cancer research.

[3]  G. Scambia,et al.  Hypoxia induces class III beta-tubulin gene expression by HIF-1alpha binding to its 3' flanking region. , 2008, Gene.

[4]  C. Dumontet,et al.  Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents? , 2008, The Lancet. Oncology.

[5]  E. Pasquier,et al.  Class III β-Tubulin Mediates Sensitivity to Chemotherapeutic Drugs in Non–Small Cell Lung Cancer , 2007 .

[6]  C. Dumontet,et al.  A20/TNFAIP3, a new estrogen-regulated gene that confers tamoxifen resistance in breast cancer cells , 2007, Oncogene.

[7]  V. Fedele,et al.  Cytoskeleton and paclitaxel sensitivity in breast cancer: The role of β‐tubulins , 2007 .

[8]  I. Skovorodkin,et al.  α-Tubulin Minichromosome Promoters in the Stichotrichous Ciliate Stylonychia lemnae , 2006, Eukaryotic Cell.

[9]  E. Martinelli,et al.  Class III β-Tubulin Overexpression Is a Marker of Poor Clinical Outcome in Advanced Ovarian Cancer Patients , 2006, Clinical Cancer Research.

[10]  J. Mackey,et al.  Class III β-tubulin expression in tumor cells predicts response and outcome in patients with non–small cell lung cancer receiving paclitaxel , 2005, Molecular Cancer Therapeutics.

[11]  C. Dumontet,et al.  Expression of Class III β-Tubulin Is Predictive of Patient Outcome in Patients with Non–Small Cell Lung Cancer Receiving Vinorelbine-Based Chemotherapy , 2005, Clinical Cancer Research.

[12]  I. Brown,et al.  The FASEB Journal express article 10.1096/fj.04-3178fje. Published online June 9, 2005. Alterations of β-tubulin isotypes in breast cancer cells resistant to docetaxel , 2022 .

[13]  R. Margueron,et al.  Transcriptional and posttranscriptional regulation of fibulin-1 by estrogens leads to differential induction of messenger ribonucleic acid variants in ovarian and breast cancer cells. , 2005, Endocrinology.

[14]  Abhilasha Gulati-Leekha,et al.  An Element in the α1-Tubulin Promoter Is Necessary for Retinal Expression during Optic Nerve Regeneration But Not after Eye Injury in the Adult Zebrafish , 2004, The Journal of Neuroscience.

[15]  M. Monden,et al.  Prediction of response to docetaxel by quantitative analysis of class I and III beta-tubulin isotype mRNA expression in human breast cancers. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[16]  G. Bepler,et al.  Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer , 2003, Oncogene.

[17]  P. Shaul,et al.  Rapid activation of endothelial NO synthase by estrogen: evidence for a steroid receptor fast-action complex (SRFC) in caveolae , 2002, Steroids.

[18]  Jingwen Liu,et al.  Requirement of Sp1 and Estrogen Receptor α Interaction in 17β-Estradiol-Mediated Transcriptional Activation of the Low Density Lipoprotein Receptor Gene Expression. , 2001, Endocrinology.

[19]  T. Nash,et al.  Initiator and upstream elements in the α2-tubulin promoter of Giardia lamblia , 2001 .

[20]  A. Santel,et al.  The initiator element of the Drosophila beta2 tubulin gene core promoter contributes to gene expression in vivo but is not required for male germ-cell specific expression. , 2000, Nucleic acids research.

[21]  S. Safe,et al.  Transcriptional activation of E2F1 gene expression by 17beta-estradiol in MCF-7 cells is regulated by NF-Y-Sp1/estrogen receptor interactions. , 1999, Molecular endocrinology.

[22]  G. Hudes,et al.  Altered beta-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells. , 1998, British Journal of Cancer.

[23]  M. Kavallaris,et al.  Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. , 1997, The Journal of clinical investigation.

[24]  K. Tew,et al.  Increase of βIII- and βIVa-Tubulin Isotypes in Human Prostate Carcinoma Cells as a Result of Estramustine Resistance , 1996 .

[25]  B. Dastugue,et al.  Intronic and 5′ flanking sequences of the Drosophila β3 tubulin gene are essential to confer ecdysone responsiveness , 1993, Molecular and Cellular Endocrinology.

[26]  B. Dastugue,et al.  Regulatory elements in the first intron contribute to transcriptional regulation of the beta 3 tubulin gene by 20-hydroxyecdysone in Drosophila Kc cells. , 1990, Nucleic acids research.

[27]  P. Chambon,et al.  Activation of pS2 gene transcription is a primary response to estrogen in the human breast cancer cell line MCF-7. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[28]  M. Pittenger,et al.  Elevation of tubulin levels by microinjection suppresses new tubulin synthesis , 1983, Nature.

[29]  Marc W. Kirschner,et al.  Unpolymerized tubulin modulates the level of tubulin mRNAs , 1981, Cell.

[30]  Sheldon Penman,et al.  Mechanisms of regulating tubulin synthesis in cultured mammalian cells , 1979, Cell.

[31]  V. Fedele,et al.  Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of beta-tubulins. , 2007, International journal of cancer.

[32]  E. Pasquier,et al.  Class III beta-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer. , 2007, Cancer research.

[33]  E. Martinelli,et al.  Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[34]  F. Kraemer,et al.  Requirement of Sp1 and Estrogen Receptor α Interaction in 17β-Estradiol-Mediated Transcriptional Activation of the Low Density Lipoprotein Receptor Gene Expression. , 2001, Endocrinology.

[35]  T. Nash,et al.  Initiator and upstream elements in the alpha2-tubulin promoter of Giardia lamblia. , 2001, Molecular and biochemical parasitology.

[36]  K. Tew,et al.  Increase of beta(III)- and beta(IVa)-tubulin isotopes in human prostate carcinoma cells as a result of estramustine resistance. , 1996, Cancer research.